These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 17113759

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME.
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study.
    Cassano GB, Jori MC, AMIMAJOR Group.
    Int Clin Psychopharmacol; 2002 Jan; 17(1):27-32. PubMed ID: 11800503
    [Abstract] [Full Text] [Related]

  • 25. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.
    Freeman HL.
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S11-7. PubMed ID: 9218163
    [Abstract] [Full Text] [Related]

  • 26. Amisulpride: a review of its use in the management of schizophrenia.
    McKeage K, Plosker GL.
    CNS Drugs; 2004 May; 18(13):933-56. PubMed ID: 15521794
    [Abstract] [Full Text] [Related]

  • 27. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR, Mahmoud R.
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [Abstract] [Full Text] [Related]

  • 28. Clinical update on amisulpride in deficit schizophrenia.
    Rein W, Turjanski S.
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S19-27. PubMed ID: 9218164
    [Abstract] [Full Text] [Related]

  • 29. Practical issues with amisulpride in the management of patients with schizophrenia.
    Pani L, Villagrán JM, Kontaxakis VP, Alptekin K.
    Clin Drug Investig; 2008 May; 28(8):465-77. PubMed ID: 18598092
    [Abstract] [Full Text] [Related]

  • 30. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H, Stensland M, Zhao Z, Kinon BJ.
    BMC Psychiatry; 2005 Jan 13; 5():3. PubMed ID: 15649317
    [Abstract] [Full Text] [Related]

  • 31. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.
    Stauffer VL, Sniadecki JL, Piezer KW, Gatz J, Kollack-Walker S, Hoffmann VP, Conley R, Durell T.
    BMC Psychiatry; 2010 Nov 03; 10():89. PubMed ID: 21047395
    [Abstract] [Full Text] [Related]

  • 32. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M, Krupka-Matuszczyk I.
    Hum Psychopharmacol; 2011 Jan 03; 26(1):81-5. PubMed ID: 23055416
    [Abstract] [Full Text] [Related]

  • 33. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
    Wetzel H, Gründer G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Schröder J, Rein W, Benkert O.
    Psychopharmacology (Berl); 1998 Jun 03; 137(3):223-32. PubMed ID: 9682999
    [Abstract] [Full Text] [Related]

  • 34. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
    Leucht S, Pitschel-Walz G, Engel RR, Kissling W.
    Am J Psychiatry; 2002 Feb 03; 159(2):180-90. PubMed ID: 11823257
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.
    Dossenbach MR, Folnegovic-Smalc V, Hotujac L, Uglesic B, Tollefson GD, Grundy SL, Friedel P, Jakovljevic MM, Olanzapine HGCH Study Group.
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar 03; 28(2):311-8. PubMed ID: 14751428
    [Abstract] [Full Text] [Related]

  • 38. Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis.
    Psarros C, Theleritis CG, Paparrigopoulos TJ, Politis AM, Papadimitriou GN.
    Int J Geriatr Psychiatry; 2009 May 03; 24(5):518-22. PubMed ID: 19072747
    [Abstract] [Full Text] [Related]

  • 39. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD.
    J Clin Psychiatry; 2008 Jul 03; 69(7):1046-56. PubMed ID: 18605811
    [Abstract] [Full Text] [Related]

  • 40. Treatment of negative symptoms in schizophrenia with amisulpride.
    Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F.
    Br J Psychiatry; 1995 Jan 03; 166(1):68-72. PubMed ID: 7894879
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.